Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Parenteral patent drug S/GSK1265744 has the potential to be an effective agent in pre-exposure prophylaxis against HIV infection.

Taha H, Morgan J, Das A, Das S.

Recent Pat Antiinfect Drug Discov. 2013 Dec;8(3):213-8.

PMID:
24738551
2.

Long-acting injectable antiretrovirals for HIV treatment and prevention.

Spreen WR, Margolis DA, Pottage JC Jr.

Curr Opin HIV AIDS. 2013 Nov;8(6):565-71. doi: 10.1097/COH.0000000000000002. Review.

3.

Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus.

Andrews CD, Spreen WR, Mohri H, Moss L, Ford S, Gettie A, Russell-Lodrigue K, Bohm RP, Cheng-Mayer C, Hong Z, Markowitz M, Ho DD.

Science. 2014 Mar 7;343(6175):1151-4. doi: 10.1126/science.1248707. Epub 2014 Mar 4.

4.

Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744.

Ford SL, Gould E, Chen S, Margolis D, Spreen W, Crauwels H, Piscitelli S.

Antimicrob Agents Chemother. 2013 Nov;57(11):5472-7. doi: 10.1128/AAC.01235-13. Epub 2013 Aug 26.

5.

Next-generation integrase inhibitors : where to after raltegravir?

Karmon SL, Markowitz M.

Drugs. 2013 Mar;73(3):213-28. doi: 10.1007/s40265-013-0015-5. Review.

PMID:
23413196
6.

New first and second generation inhibitors of human immunodeficiency virus-1 integrase.

Pendri A, Meanwell NA, Peese KM, Walker MA.

Expert Opin Ther Pat. 2011 Aug;21(8):1173-89. doi: 10.1517/13543776.2011.586631. Epub 2011 May 20. Review.

PMID:
21599420
7.

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study.

Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, Orkin C, Bloch M, Podzamczer D, Pokrovsky V, Pulido F, Almond S, Margolis D, Brennan C, Min S; SPRING-2 Study Group.

Lancet. 2013 Mar 2;381(9868):735-43. doi: 10.1016/S0140-6736(12)61853-4. Epub 2013 Jan 8.

PMID:
23306000
8.

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.

Cahn P, Pozniak AL, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva JF, Richmond G, Buendia CB, Fourie J, Ramgopal M, Hagins D, Felizarta F, Madruga J, Reuter T, Newman T, Small CB, Lombaard J, Grinsztejn B, Dorey D, Underwood M, Griffith S, Min S; extended SAILING Study Team.

Lancet. 2013 Aug 24;382(9893):700-8. doi: 10.1016/S0140-6736(13)61221-0. Epub 2013 Jul 3. Erratum in: Lancet. 2014 Jan 4;383(9911):30.

PMID:
23830355
9.

Dolutegravir, a second-generation integrase inhibitor for the treatment of HIV-1 infection.

Rathbun RC, Lockhart SM, Miller MM, Liedtke MD.

Ann Pharmacother. 2014 Mar;48(3):395-403. doi: 10.1177/1060028013513558. Epub 2013 Nov 19. Review.

PMID:
24259658
10.

Cabotegravir long-acting for HIV-1 prevention.

Andrews CD, Heneine W.

Curr Opin HIV AIDS. 2015 Jul;10(4):258-63. doi: 10.1097/COH.0000000000000161. Review.

PMID:
26049951
11.

An overview of antiretroviral pre-exposure prophylaxis of HIV infection.

McGowan I.

Am J Reprod Immunol. 2014 Jun;71(6):624-30. doi: 10.1111/aji.12225. Epub 2014 Mar 17. Review.

PMID:
24635047
12.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
13.

Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial.

van Lunzen J, Maggiolo F, Arribas JR, Rakhmanova A, Yeni P, Young B, Rockstroh JK, Almond S, Song I, Brothers C, Min S.

Lancet Infect Dis. 2012 Feb;12(2):111-8. doi: 10.1016/S1473-3099(11)70290-0. Epub 2011 Oct 20.

PMID:
22018760
14.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
15.

Dolutegravir for the treatment of HIV.

Katlama C, Murphy R.

Expert Opin Investig Drugs. 2012 Apr;21(4):523-30. doi: 10.1517/13543784.2012.661713. Epub 2012 Mar 2. Review.

PMID:
22380682
16.

Dolutegravir: a new integrase strand transfer inhibitor for the treatment of HIV.

Shah BM, Schafer JJ, Desimone JA Jr.

Pharmacotherapy. 2014 May;34(5):506-20. doi: 10.1002/phar.1386. Epub 2013 Dec 18. Review. Erratum in: Pharmacotherapy. 2014 Jun;34(6):667.

PMID:
24347095
17.

Inhibitors of HIV-1 entry and integration: recent developments and impact on treatment.

Sharma AK, George V, Valiathan R, Pilakka-Kanthikeel S, Pallikkuth S.

Recent Pat Inflamm Allergy Drug Discov. 2013 May;7(2):151-61. Review.

PMID:
23578097
18.

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.

Raffi F, Jaeger H, Quiros-Roldan E, Albrecht H, Belonosova E, Gatell JM, Baril JG, Domingo P, Brennan C, Almond S, Min S; extended SPRING-2 Study Group.

Lancet Infect Dis. 2013 Nov;13(11):927-35. doi: 10.1016/S1473-3099(13)70257-3. Epub 2013 Sep 25.

PMID:
24074642
19.

Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium.

Nguyen BY, Isaacs RD, Teppler H, Leavitt RY, Sklar P, Iwamoto M, Wenning LA, Miller MD, Chen J, Kemp R, Xu W, Fromtling RA, Vacca JP, Young SD, Rowley M, Lower MW, Gottesdiener KM, Hazuda DJ.

Ann N Y Acad Sci. 2011 Mar;1222:83-9. doi: 10.1111/j.1749-6632.2011.05972.x. Review.

PMID:
21434946
20.

Virology. A bid to thwart HIV with shot of long-lasting drug.

Cohen J.

Science. 2014 Mar 7;343(6175):1067. doi: 10.1126/science.343.6175.1067. No abstract available.

PMID:
24604173
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk